Helen McShane
University of Oxford
20
16
19
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+11 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (20)
Showing 10 of 20 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Felicity Perrin
King's College Hospital NHS Trust
Shared therapeutic areas:
Worked with same sponsors:
Marc Lipman
Royal Free Hostpital
Shared therapeutic areas:
Worked with same sponsors:
Souleymane Mboup
Centre Hospitalier Universitaire Le Dantec
Shared therapeutic areas:
Worked with same sponsors:
Gregory Hussey
University of Cape Town
Shared therapeutic areas:
Worked with same sponsors:
Alison Elliot
MRC/UVRI and LSHTM Uganda Research Unit
Shared therapeutic areas:
Worked with same sponsors:
Paul Moss
University of Birmingham
Shared therapeutic areas:
Worked with same sponsors:
François Raffi, PHD
Hopital Hotel Dieu Nantes
Shared therapeutic areas:
Gilles Pichancourt
CH Henri Duffaut Avignon
Shared therapeutic areas:
Bruno Marchou, PHD
CHU Purpan (Toulouse)
Shared therapeutic areas:
catherine GEINDRE
Assistance Publique Hopitaux De Marseille
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (20)
Showing 20 of 20 trials
Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB.
A Study of 2 Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCG
Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines
A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both
A Study to Quantify Bacille Calmette Guerin (BCG) and Characterise the Immune Response After BCG Vaccination
A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85A
Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine
A Study of MVA85A in Healthy Children and Infants
A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIV
Safety of Tuberculosis Vaccine, MVA85A, Administered by the Intramuscular Route and the Intradermal Route
A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A
Safety of Tuberculosis Vaccine, MVA85A, Administered by the Aerosol Route and the Intradermal Route
Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A
Safety Study of ChAdOx1 85A Vaccination With and Without MVA85A Boost in Healthy Adults
Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated Adults
Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA85A, as a Way to Increase Immune Response and Avoid Anti-vector Immunity
A Clinical Challenge Study of BCG in Healthy Volunteers
Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African Adolescents
MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) Infection
All 20 trials loaded